Laurel Wealth Advisors Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 6.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,995 shares of the medical research company’s stock after acquiring an additional 341 shares […]
StockNews.com upgraded shares of Amgen (NASDAQ:AMGN – Get Rating) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday. AMGN has been the topic of several other reports. Piper Sandler decreased their price objective on shares of Amgen from $293.00 to $288.00 in a report on Friday, April […]
AbCellera Biologics (NASDAQ:ABCL – Get Rating) and Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Rating) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations. Earnings & Valuation This table compares AbCellera Biologics and Ironwood […]
Weaver C. Barksdale & Associates Inc. cut its stake in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 11.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,611 shares of the medical research company’s stock after selling 1,086 shares during the quarter. Amgen […]
Grey Fox Wealth Advisors LLC bought a new stake in Amgen Inc. (NASDAQ:AMGN – Get Rating) in the fourth quarter, HoldingsChannel.com reports. The firm bought 463 shares of the medical research company’s stock, valued at approximately $122,000. A number of other hedge funds and other institutional investors also recently bought and sold shares of AMGN. […]